A Patient With Severe Asthma in Need of Additional Control

Target Audience

The educational design of this activity addresses the needs of allergy/clinical immunology and pulmonology clinicians involved in the management of patients with severe asthma.  

Program Description 

Severe asthma is thought to affect about 5% to 10% of the total population of patients with asthma. The detrimental consequences of uncontrolled severe asthma are significant, leading to serious exacerbations, deterioration of lung function, and pronounced impact on quality of life. The emergence of biologic therapies has revolutionized the treatment of severe asthma.  Dr. Flavia Hoyte consults with Dr. Njira Lugogo to discuss a patient with poorly controlled, late-onset severe disease who may be a candidate for biologic therapy.

Educational Objectives 

After completing this activity, the participant should be better able to: 

1. Describe key pathophysiologic processes in severe asthma development and persistence, including the roles of thymic stromal lymphopoietin, and implications for treatment 
2. Discuss the clinical profiles and recent trial results of newer biologic therapies for severe asthma 
3. Construct biologic-based treatment regimens for patients with severe asthma to maximize asthma control, prevent exacerbations, and incorporate shared clinical decision-making 
4. Educate patients with severe asthma to improve treatment adherence and shared decision-making

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurse and Nurse Practitioner Continuing Education 

The American Nurses Credentialing Center’s (ANCC) Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.  

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.  

Instructions to Receive Credit

In order to receive credit for this activity, the participant must: 

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity. 
2. Complete the Preactivity Questions. 
3. Review the activity content. 
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.    

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity. 

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.   

All relevant financial relationships have been mitigated.  

The faculty have the following relevant financial relationships with ineligible companies:

Flavia Hoyte, MD: Consulting Fees: AstraZeneca plc; Genentech; Contracted Research: Institution received research support from Genentech, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceutical Industries Ltd., GSK; Fees for Non-CE Services Received Directly From an Ineligible Entity or Their Agents: AstraZeneca plc; Stock Shareholder: Amgen; Merck

Njira Lucia Lugogo, MD, MS: Consulting Fees: Amgen, Inc., AstraZeneca plc, Avillion LLP, Genentech, Inc., GSK plc, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd.; Contracted Research: Institution received research support from Amgen, Inc., AstraZeneca plc, Avillion LLP, Evidera, Gossamer Bio, Genentech, Inc., GSK plc, Janssen Pharmaceuticals, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd.; Honoraria: AstraZeneca plc, GSK plc; Travel Support: AstraZeneca 

The Integritas Communication planners and managers have no relevant financial relationships to disclose. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.